JP2018505203A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018505203A5 JP2018505203A5 JP2017542165A JP2017542165A JP2018505203A5 JP 2018505203 A5 JP2018505203 A5 JP 2018505203A5 JP 2017542165 A JP2017542165 A JP 2017542165A JP 2017542165 A JP2017542165 A JP 2017542165A JP 2018505203 A5 JP2018505203 A5 JP 2018505203A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- alkyl
- aryl
- cycloalkyl
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 38
- 125000000623 heterocyclic group Chemical group 0.000 claims 38
- 125000003118 aryl group Chemical group 0.000 claims 35
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 30
- 229910052805 deuterium Inorganic materials 0.000 claims 30
- -1 hydroxy, amino Chemical group 0.000 claims 29
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 25
- 125000004103 aminoalkyl group Chemical group 0.000 claims 20
- 125000001072 heteroaryl group Chemical group 0.000 claims 16
- 125000003342 alkenyl group Chemical group 0.000 claims 15
- 125000003545 alkoxy group Chemical group 0.000 claims 15
- 125000000304 alkynyl group Chemical group 0.000 claims 15
- 239000002207 metabolite Substances 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 239000012453 solvate Substances 0.000 claims 15
- 150000001204 N-oxides Chemical class 0.000 claims 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims 14
- 239000000651 prodrug Substances 0.000 claims 14
- 229940002612 prodrug Drugs 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 13
- 201000010099 disease Diseases 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims 11
- 125000001188 haloalkyl group Chemical group 0.000 claims 11
- 125000004432 carbon atom Chemical group C* 0.000 claims 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 9
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 8
- 125000004438 haloalkoxy group Chemical group 0.000 claims 8
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 7
- 125000003282 alkyl amino group Chemical group 0.000 claims 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000004043 oxo group Chemical group O=* 0.000 claims 6
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 5
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 5
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 4
- 125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 claims 4
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 4
- 206010016654 Fibrosis Diseases 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 229940127557 pharmaceutical product Drugs 0.000 claims 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 3
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims 3
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims 3
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 201000002150 Progressive familial intrahepatic cholestasis Diseases 0.000 claims 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 210000000013 bile duct Anatomy 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 210000000232 gallbladder Anatomy 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 125000000466 oxiranyl group Chemical group 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008635 Cholestasis Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 208000012868 Overgrowth Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 206010000891 acute myocardial infarction Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000036765 blood level Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 201000001883 cholelithiasis Diseases 0.000 claims 1
- 230000007870 cholestasis Effects 0.000 claims 1
- 231100000359 cholestasis Toxicity 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 208000001130 gallstones Diseases 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 208000004235 neutropenia Diseases 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 208000015768 polyposis Diseases 0.000 claims 1
- 208000007232 portal hypertension Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 229960002477 riboflavin Drugs 0.000 claims 1
- 235000019192 riboflavin Nutrition 0.000 claims 1
- 239000002151 riboflavin Substances 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 125000000169 tricyclic heterocycle group Chemical group 0.000 claims 1
- 0 *C(*=*1)=C(CO*)*1I Chemical compound *C(*=*1)=C(CO*)*1I 0.000 description 50
- OVSYLHPLZZTPPK-UHFFFAOYSA-N CC(C)c1c(COc(cc2CCc(cc3)c4cc3C(O)=O)ccc2C4=O)[n](-c(c(Cl)ccc2)c2Cl)nn1 Chemical compound CC(C)c1c(COc(cc2CCc(cc3)c4cc3C(O)=O)ccc2C4=O)[n](-c(c(Cl)ccc2)c2Cl)nn1 OVSYLHPLZZTPPK-UHFFFAOYSA-N 0.000 description 1
- DGCCINFOBUGQPT-UHFFFAOYSA-N CC(C)c1c(COc(nc2CC3)ccc2Oc2c3ccc(C(O)=O)c2)[n](-c(c(Cl)ccc2)c2Cl)nc1 Chemical compound CC(C)c1c(COc(nc2CC3)ccc2Oc2c3ccc(C(O)=O)c2)[n](-c(c(Cl)ccc2)c2Cl)nc1 DGCCINFOBUGQPT-UHFFFAOYSA-N 0.000 description 1
- JWTATIZVPYVLKT-UHFFFAOYSA-N CCc(cc1CCc2c3cccc2)ccc1S3=O Chemical compound CCc(cc1CCc2c3cccc2)ccc1S3=O JWTATIZVPYVLKT-UHFFFAOYSA-N 0.000 description 1
- HXCRWRPVGDCJFH-UHFFFAOYSA-N COC(c1cc(Oc(c(C2C3C2)n2)ccc2OCc2c(C4CC4)[o]nc2-c(c(Cl)ccc2)c2Cl)c3cc1)=O Chemical compound COC(c1cc(Oc(c(C2C3C2)n2)ccc2OCc2c(C4CC4)[o]nc2-c(c(Cl)ccc2)c2Cl)c3cc1)=O HXCRWRPVGDCJFH-UHFFFAOYSA-N 0.000 description 1
- ADZBYRFCADJPGB-UHFFFAOYSA-N CS(NC(c1cc(Oc(c(CC2)n3)ccc3OCc3c(C4CC4)[o]nc3-c(c(Cl)ccc3)c3Cl)c2cc1)=O)(=O)=O Chemical compound CS(NC(c1cc(Oc(c(CC2)n3)ccc3OCc3c(C4CC4)[o]nc3-c(c(Cl)ccc3)c3Cl)c2cc1)=O)(=O)=O ADZBYRFCADJPGB-UHFFFAOYSA-N 0.000 description 1
- SNDHEQTYQPYSEL-UHFFFAOYSA-N CSc1cc(Oc(c(CC2)n3)ccc3OCc3c(C4CC4)[o]nc3-c(c(Cl)ccc3)c3Cl)c2cc1 Chemical compound CSc1cc(Oc(c(CC2)n3)ccc3OCc3c(C4CC4)[o]nc3-c(c(Cl)ccc3)c3Cl)c2cc1 SNDHEQTYQPYSEL-UHFFFAOYSA-N 0.000 description 1
- VYQLNYNFVHGKLB-UHFFFAOYSA-N C[n]1nc(C(O)=O)c2c1-c1cc(OCc3c(C4CC4)[o]nc3-c(c(Cl)ccc3)c3Cl)ccc1OC2 Chemical compound C[n]1nc(C(O)=O)c2c1-c1cc(OCc3c(C4CC4)[o]nc3-c(c(Cl)ccc3)c3Cl)ccc1OC2 VYQLNYNFVHGKLB-UHFFFAOYSA-N 0.000 description 1
- KHBOTBWWFUPYDQ-UHFFFAOYSA-N Cc(cc1)cc2c1Oc(cccc1)c1C=C2 Chemical compound Cc(cc1)cc2c1Oc(cccc1)c1C=C2 KHBOTBWWFUPYDQ-UHFFFAOYSA-N 0.000 description 1
- UCJYQGLMLCTOEH-UHFFFAOYSA-N Cc(cc1)cc2c1Oc1ccccc1CC2=O Chemical compound Cc(cc1)cc2c1Oc1ccccc1CC2=O UCJYQGLMLCTOEH-UHFFFAOYSA-N 0.000 description 1
- CGHZXICFAQJQIW-UHFFFAOYSA-N Cc(cc1)cc2c1Oc1ccccc1S2(=O)=O Chemical compound Cc(cc1)cc2c1Oc1ccccc1S2(=O)=O CGHZXICFAQJQIW-UHFFFAOYSA-N 0.000 description 1
- UTDPEJQJFUABQF-UHFFFAOYSA-N Cc(cc1CCc2c3cccc2)ccc1S3(=O)=O Chemical compound Cc(cc1CCc2c3cccc2)ccc1S3(=O)=O UTDPEJQJFUABQF-UHFFFAOYSA-N 0.000 description 1
- YXDDEQLSBHOBAP-UHFFFAOYSA-N Cc1ccc2Oc(cccc3)c3C=Cc2n1 Chemical compound Cc1ccc2Oc(cccc3)c3C=Cc2n1 YXDDEQLSBHOBAP-UHFFFAOYSA-N 0.000 description 1
- WBZVVEKLEITEPV-UHFFFAOYSA-N O=Sc1cc(Oc(c(CC2)n3)ccc3OCc3c(C4CC4)[o]nc3-c(c(Cl)ccc3)c3Cl)c2cc1 Chemical compound O=Sc1cc(Oc(c(CC2)n3)ccc3OCc3c(C4CC4)[o]nc3-c(c(Cl)ccc3)c3Cl)c2cc1 WBZVVEKLEITEPV-UHFFFAOYSA-N 0.000 description 1
- NCHGSQYAGQLFHQ-UHFFFAOYSA-N OC(c(cc1)cc(CCc2cc(OCc3c(C4CC4)[o]nc3-c(c(Cl)ccc3)c3Cl)ccc22)c1C2=O)=O Chemical compound OC(c(cc1)cc(CCc2cc(OCc3c(C4CC4)[o]nc3-c(c(Cl)ccc3)c3Cl)ccc22)c1C2=O)=O NCHGSQYAGQLFHQ-UHFFFAOYSA-N 0.000 description 1
- ONLLPPHAKJSQDM-UHFFFAOYSA-N OC(c(cc1)cc(CCc2n3)c1Oc2ccc3OCc1c(C2CC2)[o]nc1-c(c(Cl)ccc1)c1Cl)=O Chemical compound OC(c(cc1)cc(CCc2n3)c1Oc2ccc3OCc1c(C2CC2)[o]nc1-c(c(Cl)ccc1)c1Cl)=O ONLLPPHAKJSQDM-UHFFFAOYSA-N 0.000 description 1
- YTGLCGPNUXIJTI-UHFFFAOYSA-N OC(c(cc1)cc(CS(c2c3)(=O)=O)c1Oc2ccc3OCc1c(C2CC2)[o]nc1-c(c(Cl)ccc1)c1Cl)=O Chemical compound OC(c(cc1)cc(CS(c2c3)(=O)=O)c1Oc2ccc3OCc1c(C2CC2)[o]nc1-c(c(Cl)ccc1)c1Cl)=O YTGLCGPNUXIJTI-UHFFFAOYSA-N 0.000 description 1
- BIBVKXXJSSRWFM-UHFFFAOYSA-N OC(c(cc1)cc2c1C=Cc1nc(OCc3c(C4CC4)[o]nc3-c(c(Cl)ccc3)c3Cl)ccc1O2)=O Chemical compound OC(c(cc1)cc2c1C=Cc1nc(OCc3c(C4CC4)[o]nc3-c(c(Cl)ccc3)c3Cl)ccc1O2)=O BIBVKXXJSSRWFM-UHFFFAOYSA-N 0.000 description 1
- ZMXMCADJXDXKDS-UHFFFAOYSA-N OC(c1cc(C(c(c(CC2)c3)ccc3OCc3c(C4CC4)[o]nc3-c(c(Cl)ccc3)c3Cl)(F)F)c2cc1)=O Chemical compound OC(c1cc(C(c(c(CC2)c3)ccc3OCc3c(C4CC4)[o]nc3-c(c(Cl)ccc3)c3Cl)(F)F)c2cc1)=O ZMXMCADJXDXKDS-UHFFFAOYSA-N 0.000 description 1
- MYUKLYOYWGNVEN-UHFFFAOYSA-N OC(c1cc(C(c(c(CC2)c3)ccc3OCc3c(C4CC4)nn[n]3-c(c(Cl)ccc3)c3Cl)=O)c2cc1)=O Chemical compound OC(c1cc(C(c(c(CC2)c3)ccc3OCc3c(C4CC4)nn[n]3-c(c(Cl)ccc3)c3Cl)=O)c2cc1)=O MYUKLYOYWGNVEN-UHFFFAOYSA-N 0.000 description 1
- ALIAXGDRFBLIMA-UHFFFAOYSA-N OC(c1cc(Cc(c(CC2)c3)ccc3OCc3c(C4CC4)[o]nc3-c(c(Cl)ccc3)c3Cl)c2cc1)=O Chemical compound OC(c1cc(Cc(c(CC2)c3)ccc3OCc3c(C4CC4)[o]nc3-c(c(Cl)ccc3)c3Cl)c2cc1)=O ALIAXGDRFBLIMA-UHFFFAOYSA-N 0.000 description 1
- UQYZGCFHAXXODZ-UHFFFAOYSA-N OC(c1cc(Oc(c(CC2)c3)cnc3OCc3c(C4CC4)[o]nc3-c(c(Cl)ccc3)c3Cl)c2nc1)=O Chemical compound OC(c1cc(Oc(c(CC2)c3)cnc3OCc3c(C4CC4)[o]nc3-c(c(Cl)ccc3)c3Cl)c2nc1)=O UQYZGCFHAXXODZ-UHFFFAOYSA-N 0.000 description 1
- BTRSTRUBKLGUAR-UHFFFAOYSA-N OC(c1cc(Oc(c(CC2)n3)ccc3OCc3c(-c(c(Cl)ccc4)c4Cl)nn[n]3C3CC3)c2cc1)=O Chemical compound OC(c1cc(Oc(c(CC2)n3)ccc3OCc3c(-c(c(Cl)ccc4)c4Cl)nn[n]3C3CC3)c2cc1)=O BTRSTRUBKLGUAR-UHFFFAOYSA-N 0.000 description 1
- UFXSVFFMEZKTLA-UHFFFAOYSA-N OC(c1cc(Oc(c(CC2)n3)ccc3OCc3c(C4CC4)cn[n]3-c(c(Cl)ccc3)c3Cl)c2cc1)=O Chemical compound OC(c1cc(Oc(c(CC2)n3)ccc3OCc3c(C4CC4)cn[n]3-c(c(Cl)ccc3)c3Cl)c2cc1)=O UFXSVFFMEZKTLA-UHFFFAOYSA-N 0.000 description 1
- NDBPEPMPSZISCG-UHFFFAOYSA-N OC(c1cc(Oc(c(CC2)n3)ccc3OCc3c(C4CC4)nn[n]3-c(c(Cl)ccc3)c3Cl)c2cc1)=O Chemical compound OC(c1cc(Oc(c(CC2)n3)ccc3OCc3c(C4CC4)nn[n]3-c(c(Cl)ccc3)c3Cl)c2cc1)=O NDBPEPMPSZISCG-UHFFFAOYSA-N 0.000 description 1
- PEHXMPMZSCHSLM-UHFFFAOYSA-N OC(c1cc(S(c(c(CC2)c3)ccc3OCc3c(C4CC4)[o]nc3-c(c(Cl)ccc3)c3Cl)=O)c2cc1)=O Chemical compound OC(c1cc(S(c(c(CC2)c3)ccc3OCc3c(C4CC4)[o]nc3-c(c(Cl)ccc3)c3Cl)=O)c2cc1)=O PEHXMPMZSCHSLM-UHFFFAOYSA-N 0.000 description 1
- GOBMXBCGSBBCPW-UHFFFAOYSA-N OC(c1ccc(CCCc2nc(OCc3c(C4CC4)[o]nc3-c(c(Cl)ccc3)c3Cl)ccc2O2)c2c1)=O Chemical compound OC(c1ccc(CCCc2nc(OCc3c(C4CC4)[o]nc3-c(c(Cl)ccc3)c3Cl)ccc2O2)c2c1)=O GOBMXBCGSBBCPW-UHFFFAOYSA-N 0.000 description 1
- BUTUNTNHGZBRRP-UHFFFAOYSA-N OS(CCNC(c1cc(Oc(c(CC2)n3)ccc3OCc3c(C4CC4)[o]nc3-c(c(Cl)ccc3)c3Cl)c2cc1)=O)(=O)=O Chemical compound OS(CCNC(c1cc(Oc(c(CC2)n3)ccc3OCc3c(C4CC4)[o]nc3-c(c(Cl)ccc3)c3Cl)c2cc1)=O)(=O)=O BUTUNTNHGZBRRP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510083621 | 2015-02-13 | ||
| CN201510083621.5 | 2015-02-13 | ||
| PCT/CN2016/073617 WO2016127924A1 (en) | 2015-02-13 | 2016-02-05 | Tricyclic compounds and uses thereof in medicine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018505203A JP2018505203A (ja) | 2018-02-22 |
| JP2018505203A5 true JP2018505203A5 (https=) | 2018-11-01 |
| JP6661070B2 JP6661070B2 (ja) | 2020-03-11 |
Family
ID=56614145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017542165A Active JP6661070B2 (ja) | 2015-02-13 | 2016-02-05 | 三環式化合物および治療におけるそれらの使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10183917B2 (https=) |
| EP (1) | EP3256468B1 (https=) |
| JP (1) | JP6661070B2 (https=) |
| KR (1) | KR102577823B1 (https=) |
| CN (1) | CN105884758B (https=) |
| AR (1) | AR103574A1 (https=) |
| AU (1) | AU2016218701B2 (https=) |
| BR (1) | BR112017017078B1 (https=) |
| CA (1) | CA2976294C (https=) |
| DK (1) | DK3256468T3 (https=) |
| ES (1) | ES2791401T3 (https=) |
| HU (1) | HUE050173T2 (https=) |
| MX (1) | MX2017010477A (https=) |
| RU (1) | RU2724100C9 (https=) |
| TW (1) | TWI698430B (https=) |
| WO (1) | WO2016127924A1 (https=) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| CA2981503C (en) | 2015-03-31 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017189651A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017189663A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017201155A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF |
| US10144729B2 (en) | 2016-05-18 | 2018-12-04 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| WO2017201152A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| NZ748641A (en) | 2016-06-13 | 2020-04-24 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| TW201808283A (zh) * | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
| MA55632A (fr) | 2016-08-23 | 2022-02-16 | Ardelyx Inc | Procédé de preparation de modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques |
| US11091482B2 (en) | 2016-08-23 | 2021-08-17 | Ardelyx, Inc. | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators |
| MX2019003790A (es) | 2016-10-04 | 2019-09-26 | Enanta Pharm Inc | Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos. |
| CN107973790A (zh) * | 2016-10-22 | 2018-05-01 | 合帕吉恩治疗公司 | 杂环fxr调节剂 |
| WO2018081285A1 (en) | 2016-10-26 | 2018-05-03 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2018082596A1 (en) | 2016-11-03 | 2018-05-11 | Sunshine Lake Pharma Co., Ltd. | Solid forms of an adamantyl compound, compositions and uses thereof |
| CN106631991B (zh) * | 2016-12-16 | 2021-04-16 | 常州南京大学高新技术研究院 | 一种n-丁基-2,2,6,6-四甲基-4-哌啶胺的简便合成方法 |
| CN108329330B (zh) * | 2017-01-20 | 2021-05-04 | 复旦大学 | 2-苄氧苯基噁唑并吡啶类化合物及其药物用途 |
| SI4122464T1 (sl) | 2017-03-28 | 2024-07-31 | Gilead Sciences, Inc. | Terapevtske kombinacije za zdravljenje bolezni jeter |
| KR102643558B1 (ko) * | 2017-06-05 | 2024-03-06 | 내셔널 유니버시티 오브 싱가포르 | 인간 트레포일 인자 3을 억제하는데 유용한 화합물 |
| US11542255B2 (en) | 2017-08-15 | 2023-01-03 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| MX2020001776A (es) * | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| JP7271513B2 (ja) | 2017-09-14 | 2023-05-11 | アルデリックス， インコーポレイテッド | 代謝関連の突然変異誘発性及び線維性の症状及び障害を治療するためのホルモン受容体調節薬 |
| US12221434B2 (en) | 2017-11-09 | 2025-02-11 | Inflazome Limited | Sulfonamide carboxamide compounds |
| KR20200087759A (ko) | 2017-11-09 | 2020-07-21 | 인플라좀 리미티드 | 신규한 설폰아마이드 카복스아마이드 화합물 |
| US10689391B2 (en) | 2017-12-12 | 2020-06-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| CN110128432B (zh) * | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
| WO2019160813A1 (en) | 2018-02-14 | 2019-08-22 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| EP3759077A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| CN112805005A (zh) * | 2018-08-24 | 2021-05-14 | 拓臻股份有限公司 | 甲状腺素受体β促效剂化合物 |
| PT3911647T (pt) | 2019-01-15 | 2024-03-04 | Gilead Sciences Inc | Composto de isoxazole como agonista de fxr e composições farmacêuticas que o contenham |
| JP2022519906A (ja) | 2019-02-19 | 2022-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | Ｆｘｒアゴニストの固体形態 |
| WO2020231917A1 (en) | 2019-05-13 | 2020-11-19 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| CN110028443B (zh) * | 2019-05-29 | 2022-03-04 | 济南周行医药科技有限公司 | 一种调节fxr活性的三环化合物类药物中间体的制备方法 |
| US20220265614A1 (en) | 2019-07-23 | 2022-08-25 | Novartis Ag | Treatment comprising fxr agonists |
| EP4003349A1 (en) | 2019-07-23 | 2022-06-01 | Novartis AG | Combination treatment of liver diseases using fxr agonists |
| CN112300120B (zh) * | 2019-07-31 | 2023-04-14 | 北京四环制药有限公司 | 一种用于制备巴罗萨韦或其衍生物的化合物及其制备方法和其应用 |
| CA3153062A1 (en) | 2019-09-03 | 2021-03-11 | Novartis Ag | Treatment of liver disease or disorder comprising actrii receptor antagonists |
| JP2022548617A (ja) | 2019-09-19 | 2022-11-21 | ノバルティス アーゲー | Ｆｘｒアゴニストを含む処置 |
| JP2022550312A (ja) | 2019-09-30 | 2022-12-01 | ノバルティス アーゲー | Ｆｘｒアゴニストの使用を含む処置 |
| WO2021102204A1 (en) * | 2019-11-20 | 2021-05-27 | Vivace Therapeutics, Inc. | Heteroaryl compounds |
| US12492211B2 (en) | 2019-11-29 | 2025-12-09 | Sunshine Lake Pharma Co., Ltd. | Crystalline form of nitrogen-containing tricyclic compound and use thereof |
| AU2020390308A1 (en) * | 2019-11-29 | 2022-06-09 | Sunshine Lake Pharma Co., Ltd. | Amorphous form of nitrogen-containing tricyclic compound and use thereof |
| CN112876490A (zh) * | 2019-11-29 | 2021-06-01 | 广东东阳光药业有限公司 | 含氮三环化合物的晶型及其用途 |
| KR102803258B1 (ko) | 2019-12-10 | 2025-05-08 | 상하이 지멍 바이오파마 아이엔씨 | 신경 보호 작용을 갖는 화합물 및 이의 제조 방법과 용도 |
| US20230060422A1 (en) | 2019-12-20 | 2023-03-02 | Novartis Ag | Combination treatment of liver diseases using integrin inhibitors |
| CN115916772B (zh) * | 2020-06-19 | 2025-01-14 | 江苏恒瑞医药股份有限公司 | 6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用 |
| WO2022101853A1 (en) | 2020-11-16 | 2022-05-19 | Novartis Ag | Method of determining liver fibrosis |
| CN114235976B (zh) * | 2021-11-09 | 2023-11-03 | 暨南大学 | 一种含氮杂环有机化合物中间产物的合成和分析方法 |
| WO2024140868A1 (zh) * | 2022-12-30 | 2024-07-04 | 广东东阳光药业股份有限公司 | 三环化合物的晶型及其用途 |
| CN116283895A (zh) * | 2023-01-09 | 2023-06-23 | 怀化宝华生物科技有限公司 | 一种2-[2-(噻吩基)乙基]苯甲酸的制备方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR002459A1 (es) * | 1995-01-17 | 1998-03-25 | American Cyanamid Co | Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion. |
| JP2002532729A (ja) | 1998-12-23 | 2002-10-02 | グラクソ グループ リミテッド | 核内受容体のリガンドのアッセイ |
| IL146732A0 (en) * | 1999-06-03 | 2002-07-25 | Nippon Suisan Kaisha Ltd | Tricyclic fused heterocycle compounds, process for preparing the same and use thereof |
| ATE381542T1 (de) | 2001-08-13 | 2008-01-15 | Phenex Pharmaceuticals Ag | Nr1h4-kern-rezeptor-bindende verbindungen |
| EP1538906A2 (en) * | 2002-09-18 | 2005-06-15 | Fmc Corporation | Insecticidal tricyclic derivatives |
| JP2006515838A (ja) | 2002-11-22 | 2006-06-08 | スミスクライン ビーチャム コーポレーション | ファルネソイドｘ受容体アゴニスト |
| US8466143B2 (en) * | 2003-07-23 | 2013-06-18 | Exelixis, Inc. | Azepine derivatives as pharmaceutical agents |
| JP5081161B2 (ja) | 2005-12-19 | 2012-11-21 | スミスクライン ビーチャム コーポレーション | ファルネソイドｘ受容体アゴニスト |
| CA2640476A1 (en) | 2006-02-03 | 2007-08-16 | Eli Lilly And Company | Compounds and methods for modulating fx-receptors |
| US8703804B2 (en) * | 2006-03-26 | 2014-04-22 | Uti Limited Partnership | Ryanodine receptor inhibitors and methods relating thereto |
| US8106077B2 (en) | 2006-05-24 | 2012-01-31 | Eli Lilly And Company | Compounds and methods for modulating FXR |
| BRPI0712262A2 (pt) | 2006-05-24 | 2012-07-10 | Lilly Co Eli | agonistas de fxr |
| EP1894928A1 (en) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
| EP1894924A1 (en) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
| CL2007003035A1 (es) | 2006-10-24 | 2008-05-16 | Smithkline Beechman Corp | Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos, |
| KR20090094125A (ko) * | 2006-12-08 | 2009-09-03 | 엑셀리시스, 인코포레이티드 | Ｌｘｒ 및 ｆｘｒ 조절자 |
| WO2008157270A1 (en) | 2007-06-13 | 2008-12-24 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
| CA2690406A1 (en) | 2007-07-02 | 2009-01-08 | Glaxosmithkline Llc | Farnesoid x receptor agonists |
| TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| EP2278969B1 (en) | 2008-04-21 | 2013-02-13 | Merck Sharp & Dohme Corp. | Inhibitors of Janus kinases |
| EP2128158A1 (en) | 2008-05-26 | 2009-12-02 | Phenex Pharmaceuticals AG | Heterocyclic cyclopropyl-substituted FXR binding compounds |
| CA2736880A1 (en) | 2008-09-26 | 2010-04-01 | Wyeth Llc | 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors |
| EA022417B1 (ru) | 2008-10-21 | 2015-12-30 | Саймабэй Терапевтикс, Инк. | Арильные агонисты рецептора gpr120 и их применение |
| EP2289883A1 (en) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| AU2011218173C1 (en) | 2010-02-16 | 2015-04-16 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| WO2012087520A1 (en) | 2010-12-20 | 2012-06-28 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
| JP2014500319A (ja) | 2010-12-20 | 2014-01-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | ファルネソイドｘ受容体を調節するための組成物および方法 |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| SI3043865T1 (sl) | 2013-09-11 | 2021-04-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Metode in farmacevtski sestavki za zdravljenje virusne okužbe s hepatitisom B |
| CN104513213A (zh) | 2013-09-28 | 2015-04-15 | 山东亨利医药科技有限责任公司 | Fxr激动剂 |
| KR102350357B1 (ko) | 2013-11-05 | 2022-01-14 | 노파르티스 아게 | 파르네소이드 x 수용체의 조정을 위한 조성물 및 방법 |
| EP3116878A4 (en) | 2014-03-13 | 2018-02-14 | Salk Institute for Biological Studies | Fxr agonists and methods for making and using |
| CN104045635A (zh) | 2014-06-23 | 2014-09-17 | 华东理工大学 | 3,4,5-三取代异恶唑类化合物及其用途 |
| EP3034501A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
| EP3034499A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
| WO2016103037A1 (en) | 2014-12-22 | 2016-06-30 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
-
2016
- 2016-01-27 TW TW105102519A patent/TWI698430B/zh active
- 2016-01-29 AR ARP160100271A patent/AR103574A1/es active IP Right Grant
- 2016-02-05 BR BR112017017078-7A patent/BR112017017078B1/pt active IP Right Grant
- 2016-02-05 CN CN201610082254.1A patent/CN105884758B/zh active Active
- 2016-02-05 MX MX2017010477A patent/MX2017010477A/es unknown
- 2016-02-05 JP JP2017542165A patent/JP6661070B2/ja active Active
- 2016-02-05 DK DK16748725.5T patent/DK3256468T3/da active
- 2016-02-05 AU AU2016218701A patent/AU2016218701B2/en active Active
- 2016-02-05 HU HUE16748725A patent/HUE050173T2/hu unknown
- 2016-02-05 US US15/541,018 patent/US10183917B2/en active Active
- 2016-02-05 ES ES16748725T patent/ES2791401T3/es active Active
- 2016-02-05 CA CA2976294A patent/CA2976294C/en active Active
- 2016-02-05 RU RU2017131875A patent/RU2724100C9/ru active
- 2016-02-05 KR KR1020177025580A patent/KR102577823B1/ko active Active
- 2016-02-05 WO PCT/CN2016/073617 patent/WO2016127924A1/en not_active Ceased
- 2016-02-05 EP EP16748725.5A patent/EP3256468B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018505203A5 (https=) | ||
| RU2017131875A (ru) | Трехъядерные соединения и их применение в медицине | |
| JP2021512114A5 (https=) | ||
| JP2017514856A5 (https=) | ||
| TWI643855B (zh) | Fxr (nr1h4) 調節化合物 | |
| TWI640520B (zh) | Fxr (nr1h4) 調節化合物 | |
| TWI731392B (zh) | Fxr (nr1h4) 調節化合物 | |
| JP2017526677A5 (https=) | ||
| JP2018507914A5 (https=) | ||
| JP2016520128A5 (https=) | ||
| JP2016525136A5 (https=) | ||
| JP2017529389A5 (https=) | ||
| JP2020527588A5 (https=) | ||
| JP2017528471A (ja) | 肝疾患を処置する方法 | |
| JP2018526399A5 (https=) | ||
| JP2015521167A5 (https=) | ||
| JP2016519072A5 (https=) | ||
| JP2016506960A5 (https=) | ||
| JP2016500063A5 (https=) | ||
| JP2014500319A (ja) | ファルネソイドｘ受容体を調節するための組成物および方法 | |
| JP2020515589A5 (https=) | ||
| JP2016506962A5 (https=) | ||
| CN105085428B (zh) | 芳杂环类衍生物及其在药物上的应用 | |
| RU2019113150A (ru) | Комбинация композиций, содержащих агонисты fxr, предназначенная для лечения или предупреждения фиброзирующего, цирротического заболевания или нарушения | |
| JP2017508794A5 (https=) |